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Background: Butyrate is known as histone deacetylase inhibitor, inducing histone hyperacetylation in vitro and
playing a predominant role in the epigenetic regulation of gene expression and cell function. We hypothesized that
butyrate, endogenously produced by intestinal microbial fermentation or applied as a nutritional supplement,
might cause similar in vivo modifications in the chromatin structure of the hepatocytes, influencing the expression
of certain genes and therefore modifying the activity of hepatic microsomal drug-metabolizing cytochrome P450
(CYP) enzymes.
Methods: An animal study was carried out in chicken as a model to investigate the molecular mechanisms of
butyrate’s epigenetic actions in the liver. Broiler chicks in the early post-hatch period were treated once daily with
orally administered bolus of butyrate following overnight starvation with two different doses (0.25 or 1.25 g/kg
body weight per day) for five days. After slaughtering, cell nucleus and microsomal fractions were separated by
differential centrifugation from the livers. Histones were isolated from cell nuclei and acetylation of hepatic core
histones was screened by western blotting. The activity of CYP2H and CYP3A37, enzymes involved in
biotransformation in chicken, was detected by aminopyrine N-demethylation and aniline-hydroxylation assays from
the microsomal suspensions.
Results: Orally added butyrate, applied in bolus, had a remarkable impact on nucleosome structure of hepatocytes:
independently of the dose, butyrate caused hyperacetylation of histone H2A, but no changes were monitored in
the acetylation state of H2B. Intensive hyperacetylation of H3 was induced by the higher administered dose, while
the lower dose tended to increase acetylation ratio of H4. In spite of the observed modification in histone
acetylation, no significant changes were observed in the hepatic microsomal CYP2H and CYP3A37 activity.
Conclusion: Orally added butyrate in bolus could cause in vivo hyperacetylation of the hepatic core histones,
providing modifications in the epigenetic regulation of cell function. However, these changes did not result in
alteration of drug-metabolizing hepatic CYP2H and CYP3A37 enzymes, so there might be no relevant
pharmacoepigenetic influences of oral application of butyrate under physiological conditions.
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Short chain fatty acids (SCFA) are produced physiologic-
ally by the anaerobic microbial fermentation of dietary
compounds in the rumen of polygastric animals and
mostly fibers in the large intestine of monogastric mam-
mals, birds and humans [1]. Butyrate is of special inter-
est due to its numerous positive effects on the health of
gut and extraintestinal tissues. Butyrate is the most im-
portant energy source of the colonocytes [2], regulating
also the proliferation and differentiation of the gastro-
intestinal epithelium [3] and inducing apoptosis in gen-
etically disordered cells [4,5]. As a consequence, butyrate
has a protective effect against colorectal cancer, which
was reported in some in vitro [6] and also in vivo animal
studies [7,8]. Due to its selective antimicrobial action on
most enteral pathogens [9,10], butyrate improves the
balance of the intestinal microflora, which can influence
the health of the host animal or the human host [11].
Fiber-rich diet or uptake of resistant starch increases
microbial butyrate production, but butyrate is also orally
applicable in several forms. In animal nutrition, due to its
numerous beneficial properties improving health and also
the growth performance of pigs [12] and chickens [13],
butyrate is of special interest as a nutritional supplement,
especially after the banning of the traditional antibiotical
growth promoters in the European Union [14].
Furthermore, as an epigenetic factor, butyrate regulates
the transcription via influencing core histone acetylation,
which is one of the most relevant epigenetic regulations
of the cell function together with DNA methylation [15].
The dynamic balance of acetylation of histone proteins
at certain lysine residues is regulated by the opposing
effects of histone acetyltransferases (HAT) and histone
deacetylases (HDAC) [15]. Butyrate inhibits Class I and
most of the Class II HDAC enzymes, causing histone
hyperacetylation at lysine residues of the N-terminal tail,
therefore modifying the expression of certain genes [16].
In addition to the several in vitro studies [17], increased
total histone acetylation was reported in case of porcine
caecal tissue after dietary supplementation with the butyr-
ate precursor lactulose [18]. Butyrate-induced histone mo-
difications may be highly involved in butyrate’s antitumor,
antibacterial and metabolic effects [19].
Although butyrate is greatly metabolized by the intes-
tinal epithelium, a certain amount is also absorbed into
the portal blood [20] and taken up by the liver in rat and
human in vivo [21,22]. Butyrate is an important energy
source for the liver as a substrate of the oxidative path-
ways, but it is also a potent effector of the hepatic me-
tabolism. It can decrease the mitochondrial oxidative
phosphorylation yield and the ATP content of the liver
due to its uncoupling-like effect [23,24] and can influ-
ence the mitochondrial ATP turnover linked to glycogen
metabolism [25].It is known that the expression of certain microsomal
cytochrome P450 (CYP) monooxygenases, playing a pre-
dominant role in biotransformation, drug and steroid
metabolism, can be affected by histone modifications
[26]. For instance, the HDAC inhibitor trichostatin A
was shown to influence the in vitro expression of the
CYP3A subfamily [27]. Alimentary added inulin, which
is fermented by the colonic bacteria to SCFA, alleviates
the reduction in the expression and activity of hepatic
CYP1A1/2 and CYP2E1 enzymes in rats kept on a high-
fat diet [28], possibly due to the epigenetic effects of the
absorbed SCFA. On the basis of these findings, the enteral
microbiome-produced or the orally added butyrate may
also alter the activity of CYP enzymes, have an impact
on hepatic detoxification capacity and drug metabolism,
defined as possible pharmacoepigenetic influences.
The present study aimed to evaluate the epigenetic
effects of butyrate added orally to broiler chickens in a
daily bolus. These animals have a large capacity of gro-
wing and intensive hepatic metabolism. Young chickens
have quite low rates of butyrate production in the large
intestine [29], so they can be proper candidates in order
to study the effects of the orally applied butyrate. Unlike
in our previous study with butyrate evenly mixed in the
feedstuff of the chicken, butyrate administered in bolus
after starvation provides a fast, but short-term release of
greater amount of butyrate to the portal vein and an
intensive stimulus for the liver. The lower dose of buty-
rate, 0.25 g/kg body weight (BW) was chosen regarding
the usual applied concentration of butyrate as a nutri-
tional supplement. With the higher administered con-
centration, 1.25 g/kg BW we aimed to provide high
amount of butyrate for the hepatocytes to study also the
dose-dependency of its action.
After butyrate treatments, at first we wanted to moni-
tor the modifications in the acetylation state of hepatic
core histones at the most frequent acetylation sites. Our
second goal was to measure the activity of CYP2H and
CYP3A37 enzymes to screen, whether butyrate in bolus
can influence the detoxification capacity of the liver.
Methods
Chemicals
Chemicals were purchased from Sigma-Aldrich (Munich,
Germany) except when otherwise specified.
Animals
One-day-old broiler chicks of the Ross 308 strain (mixed
gender) were obtained from a commercial hatchery
(Bábolna Tetra Company, Uraiújfalu, Hungary). Animals
were housed individually in metal pens in a room with
controlled environment conditions of Ross technology
[30]. Feed and water were provided ad libitum. The diet
was formulated according to the requirements of the
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cal additives. Composition of the diet is shown in Table 1.
All procedures were conducted in accordance with
international and national laws and institutional guidelines
and approved by the Local Animal Test Committee of the
Faculty of Veterinary Science, Szent István University,
Budapest, Hungary (number of permission: 22.1/4719/
003/2008).
Treatments
On days 20–24 experimental animals were fasted overnight
for 12 h and thereafter treated once daily by a crop-tube
with an intraingluvial bolus according to the following
protocol: (i) ten chickens received 0.1 g/ml sodium buty-
rate solution (2.5 ml/kg BW, which equals 0.25 g sodium
butyrate/kg BW daily, 1.25 g sodium butyrate/kg BW for
the total treatment period, which is approx. 0.95 g/animal
in average); (ii) ten broilers were treated with 0.5 g/ml so-
dium butyrate solution (2.5 ml/kg BW, which equals 1.25 g
sodium butyrate/kg BW daily, 6.25 g sodium butyrate/kg
BW for the total treatment period, which is approx. 4.75 g/
animal in average); (iii) distilled water (2.5 ml/kg BW) was













Crude protein, g/kg 212.2
Ether extract, g/kg 29.4





Methionine + Cysteine, g/kg 8.6
Calcium, g/kg 11.6
Available phosphorus, g/kg 4.5
1Provided (per kilogram of diet): Se, 0.24 mg; Fe, 135 mg; Mn, 136 mg; Cu,
22 mg; Zn, 110 mg; I, 1.2 mg; retinyl acetate, 4.14 mg; cholecalciferol
0.075 mg; α-tocopherol, 26.85 mg, choline chloride, 360 mg; menadione,
3.0 mg; riboflavin, 7.0 mg; cobalamine, 0.03 mg; niacin, 40 mg; pantothenic
acid, 12 mg; folic acid, 1.0 mg; pyridoxine, 5.0 mg.did not cause any macroscopic pathomorphological altera-
tions in the mucosa of the gastrointestinal tract, which
may have been caused by higher osmolarity of the applied
solutions. In addition, (iv) six broilers were treated on days
20–24 by intracoelomal phenobarbital (PB) injection
(Phenobarbital sodium, Ph. Eur. 7.1, dissolved in sterile,
pyrogen-free and endotoxin-free physiological saline solu-
tion, applied dose: 80 mg/kg BW daily) to induce CYP ac-
tivity as a positive control. Body weight was measured
individually on each day of treatment, boli and PB injec-
tions were adjusted to the measured body weight per day.
(Mean body weight of the animals was 0.683 ± 0.011 kg on
day 20 and 0.774 ± 0.017 kg on day 24.) All animals were
starved for additional 2 h after each treatment in order to
enhance the absorption of butyrate. Daily body weight gain
and feed intake matched the requirements of the Ross
technology and no significant difference could be observed
between the groups. However, the applied butyrate pro-
vided some extra energy for the treated animals (calculated
mean metabolizable energy content of the boli was 2.8 kJ/
animal daily at the lower and 13.9 kJ/animal daily at the
higher dose), it appeared not to be relevant compared to
the energy content of the diet (calculated mean
metabolizable energy provided by the diet taken up was
1190 kJ/animal daily).
Liver sampling and separation of subcellular organelles
Animals were slaughtered in carbon dioxide anaesthesia
by decapitation on day 24. Last treatment was conducted
2 h prior to slaughtering. After opening the coelom, the
liver was exsanguinated with chilled physiological saline
solution through the portal vein and was ectomized,
weighed and shock-frozen immediately in liquid
nitrogen.
After thawing, cell nucleus fraction was isolated from
the liver of the bolus-treated and control chickens (treat-
ments i, ii, iii) in order to examine the acetylation state
of the core histones, while microsomal fractions were
prepared from all animals (treatments i, ii, iii, iv) to
study the hepatic CYP activity.
Subcellular organelles were isolated by differential cen-
trifugation according to the protocol of Van der Hoeven
[31]. Microsomal total protein concentration was deter-
mined with a Bicinchoninic Acid Protein Assay Kit (Fisher
Scientific, Rockford, IL, USA) on a microplate in tripli-
cates, using bovine serum albumin (BSA) as a standard.
All cell nucleus and microsomal fractions were shock-
frozen in liquid nitrogen and were stored at −80°C until
further examinations.
Histone isolation
Purified histone extracts were isolated by a Histone Purifi-
cation Mini Kit (Active Motif, Carlsbad, CA, USA) from
cell nucleus fractions according to the manufacturer’s
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reagents prevented further deacetylase activity to ensure
acetylation status as in vivo.
Equal volume of ice-cold Extraction Buffer was added to
the nucleus suspension. After homogenization, samples
were incubated overnight at 4°C on a rotating platform.
Tubes were centrifuged at maximum speed (30,000 g) for
5 min in a microfuge, and the supernatant, considered as
the crude histone extract, was neutralized with one-fourth
volume of 5x Neutralization Buffer (pH 8.0). Neutralized
extract was loaded onto previously equilibrated histone
isolation spin columns. After 3 washing steps with Wash
Buffer, histones were eluted and precipitated overnight
from the flow-through by 4% perchloric acid. Precipitate
was sedimented by centrifugation at 30,000 g for 60 min,
the pellet was washed at first with 4% perchloric acid, later
with acetone, containing 0.2% HCl and finally with pure
acetone. Histones were resuspended in sterile distilled
water and the yield of total core histone proteins was
quantified by measuring the absorbance at 230 nm.
Western blot analysis
Electrophoresis and western blotting were performed
according to the instructions of the applied Acetyl Histone
Antibody Sampler Kit (Cell Signaling, MA, USA). Histone
preparations were diluted by SDS- and mercaptoethanol-
containing loading buffer (supplemented with 50 mM
dithiothreitol), sonicated for 15 sec in order to reduce vis-
cosity and proteins were heat denatured at 95°C for 5 min.
Histones were separated by SDS-PAGE on polyacrylamide
(4-20%) precast gradient gels (Biorad Laboratories, CA,
USA), the amount of loaded protein was 3 μg per lane for
the detection of histones H2A and H3, while 6 μg per lane
for histones H2B and H4. After tank blotting of proteins
onto nitrocellulose membranes (0.2 μm pore size, Biorad
Laboratories, CA, USA), histones were identified by
immunodetection using antibodies of the Acetyl Histone
Antibody Sampler Kit: after blocking with 5% fat-free
milk-containing PBST for 2 h, the immunoblots were
incubated overnight with primary antibodies against his-
tone H2A (1:1000), H2B (1:500), H3 (1:1000), H4 (1:500)
and their acetylated forms. Each acetyl histone antibody
was specific for the target histone modified at the lysine
residue of the most frequent acetylation site (H2A and
H2B: Lys 5, H3: Lys 9, H4: Lys 8). Detection of the
primary antibody was performed using an anti-rabbit
secondary antibody (1:2000) coupled with horseradish
peroxidase. Primary antibodies were diluted in PBST, con-
taining 5% BSA, while secondary antibodies in PBST, con-
taining 5% fat-free milk. Bands were detected by the
Chemidoc XRS enhanced chemiluminescence system
(Biorad Laboratories, CA, USA). Membranes were finally
stained by Indian Ink to detect all the separated proteins.
Band intensities were quantified by the Quantity One 1-DAnalysis software (Biorad Laboratories, CA, USA), trace
quantities were standardized to the Indian Ink stained
bands to ensure equal loading. Acetylation ratios were
determined considering relative protein expression levels
of each histone and its acetylated form.
All western blot examinations were carried out in
duplicates. Regarding histone H3, due to their different
molecular mass, trace quantities of bands representing
H3.1 and H3.2 isoforms could be measured separately,
but the acetylation state was calculated from the total
amount of H3 and acetyl-H3.
Enzyme assays on hepatic microsomal CYP activity
Aminopyrine N-demethylation assay
Microsomal CYP2H/CYP3A37 activity was screened by
the aminopyrine N-demethylation assay, in which for-
maldehyde production could be measured by the spec-
trophotometric method of Nash [32]. The enzyme assay
was performed according to the modified protocol of
García-Agúndez et al. [33]. The reaction mixture con-
tained an NADPH+H+-regenerating cofactor mixture,
prepared from 0.5 mM NADPH+H+ (Reanal Private
Ltd., Budapest, Hungary), 50 mM glucose 6-phosphate,
4 IU/l glucose 6-phosphate dehydrogenase, 5 mM MgCl2
and 50 mM semicarbazide.
After thawing on ice, 100 μl microsomal suspension
was incubated with 200 μl cofactor mixture and 900 μl
0.05 M phosphate buffer (pH 7.4) in the presence of dif-
ferent concentrations (0, 1.25, 2.5, 5, 10 mM) of
dimethylamino-antipyrine (aminopyrine) for 10 min at
37°C. The reaction was stopped by adding 200 μl 20%
trichloroacetic acid. After centrifugation at 4,500 g for
10 min, 400 μl Nash reagent (0.16 ml acetyl acetone and
0.24 ml concentrated acetic acid in 20 ml of 4 M ammo-
nium acetate solution) was added to 800 μl of the super-
natant. The mixture was incubated at 60°C for 30 min,
cooled down on ice and the absorbance was measured
spectrophotometrically at 415 nm against reagent blank.
Results were corrected by subtracting the absorbance of
an inhibited blank per each substrate concentration
(inhibited previously by adding 20% trichloroacetic acid).
Formaldehyde standard curves were determined under the
same conditions as used for microsomal activity measure-
ments; each sample was examined in triplicates. Finally,
mean specific enzyme activity (reaction velocity), maximal
reaction velocity (Vmax) and the Michaelis-Menten’s con-
stant (KM) were calculated and compared between groups.
All results were standardized according to the total protein
concentration of microsomal samples.
Aniline-hydroxylation assay
CYP2H activity was measured by aniline-hydroxylation
assay. The enzyme assay was carried out according to the
modified protocol of Murray and Ryan [34]. The reaction
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mixture with the same composition as for the aminopyr-
ine N-demethylation assay. After thawing on ice, 100 μl
microsomal suspension was incubated with 200 μl cofac-
tor mixture and 900 μl 0.05 M phosphate buffer (pH 7.4)
and different concentrations (0, 1.25, 2.5, 5, 10 mM) of an-
iline hydrochloride for 15 min at 37. The reaction was ter-
minated by adding 200 μl 20% trichloroacetic acid.
Following centrifugation at 4,500 g for 10 min, 400 μl 10%
Na2CO3 solution and 400 μl alkaline phenol solution
(0.8% phenol solution in 0.2 M NaOH) were added to
400 μl of the supernatant. The mixture was incubated at
37°C for 30 min, cooled down on ice and the absorbance
was measured by spectrophotometer at 605 nm against
reagent blank. An inhibited blank was approved for each
substrate concentration similarly to the aminopyrine
N-demethylation assay. To determine the amount of the
produced 4-aminophenol, standard curves were prepared;
each sample was examined in triplicates. Mean specific
enzyme activity, Vmax and KM values were also determined
and compared between groups. All results were standar-
dized according to the total protein concentration of
microsomal samples.
Statistics
All values are expressed as means ± SEM. Statistical
analysis of data was performed with R 2.14.0 soft-
ware (downloaded from http://cran.r-project.org/bin/win-
dows/base/old/2.14.0/ on 14 December 2011), one-tailed
non-parametric Mann-Whitney’s test and one-way
ANOVA were approved for comparison of results of the
treated groups with those of controls. Level of significance
was set at P<0.05.
Results and discussion
Acetylation of hepatic core histones
Screening of the important acetylation sites of core his-
tones showed that butyrate treatment in bolus at the
lower dose (0.25 g/kg BW) tended to increase acetyl-
ation of histone H2A at lysine 5 (P=0.063), and the
higher applied dose (1.25 g/kg BW) caused significant,
approximately twofold increase in acetylation (P=0.048)
compared to the control group at the same acetylation
site of H2A (Figure 1A and Figure 2).
Confirming this finding, butyrate induced hyperacety-
lation of H2A in colonic epithelial cell culture in vitro
[35]. Acetylation of H2A is of special importance since
its acetylation state is highly involved in conformational
changes of the nucleosome and decreased histone-DNA
interactions, working synergistically with acetylation of
the N-terminal histone tails [36,37].
In contrast, butyrate bolus did not influence the
acetylation of histone H2B at lysine 5 with the lower
(P=0.274) nor the higher dose of butyrate (P=0.714)(Figure 1B and Figure 2). There are still some other ly-
sine residues in H2B, which may be potential targets of
HDAC inhibitors [38], and possible effects of butyrate
on these other acetylation sites cannot be excluded.
There was no significant difference in the acetylation
ratio of total histone H3 at lysine 9 after the application
of butyrate in the lower dose (P=0.146). However, higher
dose of butyrate caused relevant, approximately 18-fold
increased H3 acetylation ratio (P=0.009) (Figure 1C and
Figure 2). Hyperacetylation of H3 after butyrate expo-
sure was reported by several in vitro studies in a variety
of cultured mammalian cells, but not yet described
in vivo. It was found already in 1973 that butyrate in
millimolar concentrations caused hyperacetylation of H3
and H4 in all examined vertebrate cell lines, while H2A
and H2B were also affected in certain rat-derived cell
cultures [17]. Butyrate-induced dynamic histone acetyl-
ation was compared between mammalian and avian cells
in vitro [16], where huge amount of highly acetylated H3
isoforms was found after butyrate treatment in human
breast cancer cells, in contrast of terminally differen-
tiated avian immature erythrocytes, 2% of which partici-
pated in the acetylation process. Among the many
acetylation sites, in agreement with our results, it was re-
cently described that butyrate induced H3 hyperacetylation
first of all at lysine 9, an acetylation site that plays a critical
role in the epigenetic regulation of cell function [39]. Since
this acetylation site is linked to histone phosphorylation
and methylation processes, these site-specific modifica-
tions together can cause distinct chromatin alterations and
cell cycle modifications [40].
The H3 isoforms H3.1 and H3.2 could be also separated
on the immunoblots and it was found that butyrate
increased the relative protein expression level of the H3.1
isoform, which was poorly expressed in control animals,
but was detected in high amount in both butyrate-treated
groups. The difference in the relative protein expression
level of H3.1 between the control and butyrate-treated
groups was considered to be significant after the applica-
tion of the lower dose (P=0.021) and a near-significant
trend following treatment with the higher dose (P=0.090)
of butyrate. It is known that three H3 variants (H3.1,
H3.2, H3.3) do exist in mammals, specifically, H3.1 is
involved in both chromatin activation and repression,
while H3.2 plays an important role in gene repression and
H3.3 is especially enriched in active marks [41]. Unlike in
the case of mammals, only H3.1 and H3.2 could be sepa-
rated from chicken cells [42]. Due to the pleiotropic effect
of H3.1 on transcription, increased protein expression
level of H3.1 after butyrate treatment, detected in our
present study, may be also of special importance.
Regarding the acetylation of histone H4 at lysine 8, bu-
tyrate tended to induce hyperacetylation at the lower
administered dose (P=0.063) (Figure 1D and Figure 2).
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Figure 1 A-D. Relative acetylation of hepatic core histones in chicken after oral application of butyrate bolus. Butyrate was applied at a
lower (0.25 g/kg BW) and a higher (1.25 g/kg BW) dose, relative acetylation ratios were compared to those of controls (considered as 100%).
Acetylation ratios were determined considering relative protein expression levels of each histone and its acetylated form. Data are presented as
mean ± SEM (n=6/group). *Significant difference, P<0.05; **Significant difference, P<0.01.
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butyrate-induced hyperacetylation in cell cultures [17]. It
is known that acetylation and deacetylation of H4 is a
well-coordinated process, and butyrate-induced tetra-
and tri-acetylated forms of H4 are always acetylated at
lysine 8 [38]. Therefore, the lysine residue examined in
this study is considered as one of the most important
acetylation sites of H4. It was recently also stated that
H3 at lysine 9 and H4 at lysine 8 are critical targets
of butyrate-induced histone hyperacetylation, which
process is associated with the G-protein-coupled recep-
tor-41, also activated by butyrate [43]. Interestingly, the
acetylation ratio of H4 after force-feeding with the
higher dose of butyrate was not increased significantly
compared to the control group (P=0.210) (Figure 1D
and Figure 2). Butyrate can also alter the activity of HAT
enzymes, and this contradictory finding may be in asso-
ciation with the pleiotropic effects of butyrate on HAT
and HDAC [44], depending also on the dose of butyrate.
Very little data can be found in literature regarding
the in vivo effects of butyrate on the chromatin struc-
ture. In a recent study, significant increase in total his-
tone acetylation was reported in the caecal tissue of pigs
after receiving orally administered lactulose, which was
intensively fermented to butyrate in the large bowel [18].
It is also interesting to compare the present results
after butyrate application in bolus with our recent ex-periment [45], where butyrate was applied as a nutri-
tional supplement for broiler chickens for three weeks at
the concentration of 1.5 g/kg diet. Dosage of butyrate as
a supplement was approximately equivalent with the
lower dose bolus (0.25 g/kg BW) in the present study.
The most important difference between the treatments
is that the administration of butyrate in bolus after over-
night starvation provides a short-term supply of greater
amount of butyrate for the hepatocytes. In the earlier ex-
periment animals could take up butyrate-supplemented
diet the whole day, but this uptake might be followed by
a prolonged absorption and a long-acting butyrate ex-
posure of the liver.
In both experiments, hyperacetylation of H2A at lysine
5 was found and no dose-dependency could be detected
after bolus treatment. In spite of these results, it can be
stated that butyrate did not affect the acetylation state of
histone H2B at lysine 5 after butyrate administration in
bolus, nor in the nutritional supplement study. Similarly
to our earlier experiment, where butyrate was applied as
a nutritional supplement, the lower dose of butyrate
bolus did not cause any changes in the acetylation of
histone H3 at lysine, but the higher dose induced a
highly relevant hyperacetylation of H3 at lysine 9. Due
to the key-role of H3 modifications in gene expression
[39,40], this action seems to be a very important change
in the epigenetic regulation of transcription. Lower dose
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Figure 2 Representative bands as obtained by western blotting from isolated hepatocyte histones of chickens. Columns show the bands
of control animals (C) and chicks after oral application of butyrate bolus at the dose of 0.25 g/kg body weight (BL) and the dose of 1.25 g/kg
body weight (BH). The upper rows show the relative protein expression levels of total H2A, H2B, H3 and H4, respectively, while the bands specific
for acetylated histones of the same animals can be seen below (AcH1-4). At histone H3, the upper band can be identified as the H3.1 isoform
and the lower as H3.2. Western blots were done in duplicates for all histones.
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8, differing from the nutritional supplement experiment,
underlining the critical role of the application.
We can summarize that orally applied butyrate in bolus
influenced hepatic histone acetylation in vivo, core his-
tones H2A, H3 and H4 were involved in this partly dose-
dependent action. Since butyrate modified the chromatin
structure, it can be considered as an important epigenetic
effector on gene expression of hepatocytes. Therefore, he-
patic CYP activity was measured as key surrogate to assess
changes in gene expression and subsequently, function.Activity of hepatic microsomal CYP enzymes
We hypothesized that butyrate-induced histone modifi-
cations might cause changes in hepatic CYP activity; be-
cause it was reported that histone acetylation had a huge
impact on gene expression of several members of the
CYP2 family [26]. It is also known that alterations in his-
tone H3 acetylation are involved in the expression of
CYP3A subfamily in the adult mouse [46]. However, in
our experiment, butyrate-induced epigenetic changes of
chromatin structure did not result in changes of enzyme
activity.Screening the aminopyrine N-demethylation activity of
hepatic microsomal fractions, catalyzed by CYP2H and
CYP3A37 enzymes, no significant difference was found
between the mean enzyme activity (reaction velocity) of
the butyrate-treated animals and those of controls (lower
dose: P=0.196, higher dose: P=0.523) (Figure 3A). Simi-
larly, administration of butyrate bolus caused no signifi-
cant differences in the Vmax values, independently of the
applied dose (lower dose: P=0.368, higher dose: P=0.911).
The lower concentration of butyrate did not affect the KM
value (P=0.713), but the higher dose tended to decrease it
(P=0.095), however, due to high standard error of mean it
can be considered only as a near-significant trend (Table 2).
As an enzyme inductor, PB treatment caused notable en-
zyme induction with significantly increased mean reaction
velocity (P=0.003) (Figure 3A) and Vmax values (P=0.009),
but did not influence the KM (P=0.878) of the reaction
(Table 2).
In agreement with these results, butyrate treatment in
bolus did not alter the aniline-hydroxylation activity of the
liver, specific for the microsomal CYP2H subfamily. No
significant difference was found in the mean enzyme ac-
tivity (lower dose: P=0.211, higher dose: P=0.848) (Figure 3B),

























































Figure 3 Mean specific activity of hepatic microsomal CYP
enzymes of chickens. A. Average amount of formaldehyde
produced in aminopyrine N-demethylation assay (μmol per minute
per mg microsomal protein), indicating the mean specific activity of
hepatic microsomal CYP2H/CYP3A37 isoenzymes. B. Average
amount of 4-aminophenol produced in aniline-hydroxylation assay
(μmol per minute per mg microsomal protein), indicating the mean
specific activity of hepatic microsomal CYP2H isoenzyme. Results of
enzyme assays, carried out with the hepatic microsomal fraction of
chickens after oral application of butyrate bolus at a lower (0.25 g/kg
BW, n=10) and a higher (1.25 g/kg BW, n=9) dose or treated with
intracoelomal phenobarbital (PB) injection (80 mg/kg BW, n=6), are
compared to those of controls (n=9). Data are presented as mean ±
SEM. **Significant difference, P<0.01.
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(Table 2) between control and butyrate-stimulated chickens,
independently of the applied dose.
PB treatment enhanced significantly the CYP2H acti-
vity: increased mean reaction velocity (P=0.002) was
measured (Figure 3B), but Vmax (P=0.267) and KM values
were not affected (P=0.760) (Table 2).Table 2 Effects of oral application of butyrate on kinetic prop
Enzyme action Responsible CYP Kinetic parameter Co
Aminopyrine
N-demethylation
CYP2H/3A37 Vmax (μmol/mg/min) 0.22
KM (mM) 1.07
Aniline-hydroxylation CYP2H Vmax (μmol/mg/min) 0.11
KM (mM) 5.27
1Values are shown as means ± SEM (control: n=9; butyrate, lower dose: n=10; butyr
2Butyrate = chickens treated with oral application of butyrate bolus in a lower (0.25
3PB = chickens received intracoelomal phenobarbital injection (80 mg/kg BW) on d
**Significant difference, P<0.01.These data are in agreement with our previous results
[45], where we found that butyrate as a feed supplement
did not alter the activity of hepatic CYP2H and CYP3A37
enzymes in chicken. Now, on the basis of our previous
and recent results, it can be stated, that independently of
the form of application and the applied dose, alimentary
butyrate did not modify the activity of the examined CYP
enzymes under physiological conditions.
However, butyrate’s potential effects on other CYP sub-
families cannot be excluded. It is also not clear, whether
under special dietary conditions or simultaneously applied
with other agents, such as xenobiotics, butyrate may mod-
ify the liver enzymes of biotransformation. For example,
dietary supplementation of inulin, a precursor of colonic
butyrate production, in rats, suffering from high-fat-diet-
induced hyperlipidaemia and hepatic steatosis, counter-
acted the decrease in the expression and activity of hepatic
CYP1A1/2 and CYP2E1 enzymes [28].Conclusion
The present study indicated that (1) orally applied butyr-
ate in bolus had an impact on chromatin structure of
hepatocytes in chicken in the early post-hatch period: in-
dependently of the dose, butyrate caused hyperacetyla-
tion of histone H2A, but no changes were observed in
the acetylation state of H2B. The higher administered
dose (1.25 g/kg BW) induced an intensive hyperacetyla-
tion of H3, while the application of the lower dose
(0.25 g/kg BW) tended to increase acetylation ratio of
H4. In addition, both treatments with butyrate bolus
increased the expression of the H3.1 isoform. (2) These
changes in the epigenetic regulation of cell function did
not result in alteration of drug-metabolizing hepatic
CYP2H and CYP3A37 enzyme activity, so there might
be no relevant pharmacoepigenetic influences of orally
applicated butyrate under physiological conditions.
Results of this and former studies indicate that grow-
ing chicken are a suitable model to evaluate the epigen-
etic effects of orally applied butyrate both by diet and by
intra-crop application. Due to low endogenous butyrateerties of cytochrome P450 (CYP) enzymes in chicken1





± 0.06 0.21 ± 0.04 0.17 ± 0.03 0.38 ± 0.01**
± 0.24 1.20 ± 0.33 0.57 ± 0.15 1.02 ± 0.14
± 0.02 0.15 ± 0.04 0.13 ± 0.03 0.19 ± 0.01
± 0.48 12.25 ± 4.36 7.86 ± 2.55 3.27 ± 0.45
ate, higher dose: n=9; PB: n=6).
g/kg BW) and a higher (1.25 g/kg BW) dose.
ays 20–24.
Mátis et al. Nutrition & Metabolism 2013, 10:12 Page 9 of 10
http://www.nutritionandmetabolism.com/content/10/1/12production the histone acetylation is most likely derived
from exogenous butyrate directly. Although this is a
strictly descriptive study, this chicken model provides a
high potential to identify butyrate-induced epigenetic
mechanisms and their consequences in metabolic regu-
lation in future.
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